Creatine
Creatine is an energy store produced by the body; human studies show benefits for strength and muscle mass, but mixed results for performance and the brain.
We evaluated 367 human studies on Creatine, including 165 randomised controlled trials and 70 meta-analyses or systematic reviews; the controlled studies include 8,940 participants in total. As of 3 October 2026.
1. What Is Creatine? Occurrence, Origin and Forms
Creatine is a substance the body makes itself in the liver, kidneys and pancreas from three amino acids. As creatine phosphate it serves as a rapid energy store in muscles and the brain.
Food provides creatine mainly from meat and fish; vegetarian and vegan diets lack this source.
Creatine for supplements is made chemically, mostly as creatine monohydrate, which is the form used in most studies.
Forms and Preparations Studied
- Creatine monohydrate
- Other creatine forms (hydrochloride, ethyl ester, buffered creatine)
- Loading phase with a high dose and maintenance dose
- Combination products with creatine – the other ingredients are named in each case
Not covered on this page:
- Creatine kinase and creatinine as laboratory values without creatine supplementation
2. What Does Creatine Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Strength and muscle mass | mixed | high | 30 meta-analyses · 102 controlled · 33 other | 1,122 |
| Sprint and endurance performance | mixed | high | 13 meta-analyses · 78 controlled · 23 other | 698 |
| Muscles and bones in older age | mostly no difference | high | 16 meta-analyses · 19 controlled · 17 other | 193 |
| Memory and brain | mixed | high | 12 meta-analyses · 21 controlled · 25 other | 379 |
| Mood and depression | mixed | high | 3 meta-analyses · 12 controlled · 9 other | 140 |
| Kidney values and tolerability | mostly no difference | low | 7 meta-analyses · 26 controlled · 23 other | 474 |
| Other outcomes | mixed | high | 24 meta-analyses · 141 controlled · 62 other | 8,324 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Creatine, Strength and Muscle Mass: Human Studies
Creatine with strength training increased maximal strength more than placebo in several meta-analyses, for example in bench and chest press 381422. Isometric muscle strength was also higher than with placebo in several controlled studies 8990216. Fat-free mass improved in several controlled studies 8793. Handgrip strength improved in several controlled studies 156231. Muscle mass was improved in several controlled studies 155256. The number of repetitions and Wingate performance were higher than with placebo in two controlled studies 146198. Muscle thickness increased more with creatine than with placebo in one controlled study 174. Individual strength measures such as leg press, upper body strength or knee extension showed no established difference in the same meta-analyses 31822. Several controlled studies also found no difference in muscle strength 101107113. Several controlled studies found no difference in fat-free mass 101107188. Several controlled studies found no difference in isometric strength 124202226. One meta-analysis and one controlled study found no difference in handgrip strength 393. During immobilization of the leg, creatine did not preserve muscle mass better than placebo 108. One controlled study found no difference in muscle thickness 180. The findings apply to creatine monohydrate, sometimes with a loading phase and maintenance dose, usually in combination with strength training. Creatine monohydrate with conjugated linoleic acid increased strength and fat-free mass more than placebo in older people 97; with HMB, the results were inconsistent 66. The evidence is strong, but many studies were small and short, and the heterogeneity between populations, training protocols and dosages leaves open for whom and under what conditions the benefit is greatest.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Kreider et al. 2025 | systematic review · 12,839 participants | Creatine, mostly creatine monohydrate; mean 0.166 g/kg/d (about 12.5 g/d); mean 64.7 days, studies up to 14 yrs; vs. Placebo (13,452 participants in 652 studies) | Muscle cramping/pain (study percentage): worsened (PLA 0.9%, Cr 2.9%, p = 0.008); Muscle cramping/pain (participant percentage): no difference (PLA 0.07%, Cr 0.52%, p = 0.085) |
| 3 Kazeminasab et al. 2025 | meta-analysis · 1,937 participants | Creatine supplementation; vs. Placebo | Bench/chest press strength: improved (WMD = 1.43 kg, p = 0.002); Squat strength: improved (WMD = 5.64 kg, p = 0.001); Handgrip strength: no difference (WMD = 4.26 kg, p = 0.10) |
| 5 Wang et al. 2026 | meta-analysis · 1,211 participants | Creatine supplementation (compared with protein and omega-3); vs. Protein, omega-3 supplementation and control | Muscle strength (SMD): improved (SMD = 0.46, 95% CI: 0.29 to 0.63, SUCRA = 82.4%) |
| 6 Delpino et al. 2022 | meta-analysis · 1,192 participants | Creatine supplementation; vs. Placebo or control, with/without exercise | Lean body mass (all studies): improved (0.68 kg (95% CI, 0.26-1.11)); Lean body mass with resistance training: improved (1.10 kg; 95% CI, 0.56-1.65); Lean body mass with mixed exercise: no difference (0.74 kg; 95% CI, -3.89 to 5.36) |
| 8 Sharifian et al. 2025 | meta-analysis · 1,093 participants | Creatine supplementation plus exercise training; vs. Placebo plus exercise training | 1RM (kg): improved (mean difference = 2.122, Z = 3.255, P = 0.001) |
| 9 Davies et al. 2024 | meta-analysis · 1,076 participants | Creatine supplementation; vs. Placebo | Upper-body muscle strength: improved (SMD: 0.25; 95% CI: 0.06-0.44; I2 = 0%; P = 0.01); Handgrip strength: improved (SMD 0.23; 95% CI: 0.01-0.45; I2 = 0%; P = 0.04) |
| 10 Davies et al. 2023 | meta-analysis · 1,076 participants | Creatine supplementation; vs. Placebo | Upper body muscle strength: improved (SMD 0.25, 95% CI 0.06 to 0.44; I =0%; p=0.01); Handgrip strength: improved (SMD 0.23, 95% CI 0.01 to 0.45; I =0%; p=0.04) |
| 13 Chen et al. 2026 | meta-analysis · 763 participants | Creatine monohydrate (3 studies) plus structured exercise; vs. Exercise alone or placebo plus exercise | Bench press strength: improved (g=0.279, 95% CI: 0.008 to 0.550, p=0.043); Handgrip strength: improved (g=0.412, 95% CI: 0.039 to 0.786, p=0.031); Skeletal muscle mass: no difference (g=0.065, 95% CI: -0.353 to 0.482, p=0.762) |
Further studies in this area: 14 16 18 22 25 29 31 38 41 42 43 44 45 47 50 53 55 60 61 63 64 65 66 67 69 70 80 87 89 90 93 94 97 98 100 101 102 103 107 108 109 112 113 114 115 116 117 120 121 122 123 124 125 126 127 133 134 136 137 141 143 144 145 146 147 152 155 156 157 160 161 162 163 164 167 170 173 174 175 176 178 180 181 183 187 192 193 194 198 199 200 201 202 206 208 209 211 213 214 216 218 223 224 225 226 229 231 233 234 235 237 242 243 244 248 249 252 254 256 257 258 261 263 265 266 273 274 276 283 285 288 291 296 305 307 308 309 310 311 312 321 322 323 324 330 332 334 335 337 339 346 352 353 356 358 360 362
Creatine, Sprint and Endurance Performance: Human Studies
For sprint and endurance performance, the picture is mixed. Several controlled studies found better sprint performance than with placebo 131215248, while others found no difference, for example in swimmers 21232. Meta-analyses showed advantages for Wingate performance and anaerobic performance, but not for aerobic performance 365. In active women, creatine monohydrate improved the fatigue index in repeated sprints, especially in the high-hormone cycle phase; heart rate variability remained unchanged 96. The findings apply predominantly to creatine monohydrate, sometimes with a loading phase and maintenance dose. Buffered creatine monohydrate (Kre-Alkalyn) did not perform better than creatine monohydrate (Creapure) in the Wingate test 98. A systematic review of alternative creatine forms such as magnesium chelate, citrate, malate, ethyl ester, nitrate and pyruvate found no consistent performance improvement over placebo 57. Creatine monohydrate with maltodextrin showed no differences in sprint time, fatigue index and blood lactate 88. Creatine monohydrate plus conjugated linoleic acid improved muscular endurance and isokinetic knee extension strength 97. Creatine monohydrate plus HMB improved anaerobic performance in some of the studies; the only study on aerobic performance found no advantage 66. The evidence is strong, but the heterogeneity between studies, populations and training support leaves open for whom and under what conditions the benefit is greatest.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Kazeminasab et al. 2025 | meta-analysis · 1,937 participants | Creatine supplementation; vs. Placebo | Vertical jump: improved (WMD = 1.48 cm, p = 0.01); Wingate peak power: improved (WMD = 47.81 Watts, p = 0.004) |
| 5 Wang et al. 2026 | meta-analysis · 1,211 participants | Creatine supplementation (compared with protein and omega-3); vs. Protein, omega-3 supplementation and control | Endurance performance (SMD): no difference |
| 20 Gras et al. 2023 | systematic review · 424 participants | Creatine supplementation (form not stated); vs. Placebo | change in VO2max: worsened (ES = -0.32, 95%CI = -0.51 to -0.12, p = 0.002); VO2max after supplementation: worsened (ES= -0.20, 95%CI = -0.39 to -0.001, p = 0.049) |
| 21 Huang et al. 2024 | meta-analysis · 361 participants | Creatine supplementation; vs. Placebo | Single sprint swimming time: no difference (SMD: -0.05, 95% CI: -0.26, 0.15; p = 0.61); Repeated interval swimming: no difference (SMD: -0.11; 95% CI: -0.46, 0.25; p = 0.56) |
| 23 Aguinaga-Ontoso et al. 2023 | systematic review · 310 participants | Creatine supplementation (form not specified); vs. Other nutrition interventions or control | Soccer performance (endurance, speed, agility, strength, power, explosiveness): improved |
| 26 Metzger et al. 2023 | systematic review · 268 participants | Creatine supplementation; vs. Randomized controlled trials in over 75% of studies | Athletic performance: unclear |
| 37 Wesołowski et al. 2026 | systematic review | Creatine monohydrate; Loading 20 g/day, sometimes maintenance 2-5 g/day; Loading phase 5-7 days; vs. Placebo or baseline values | Repeated-sprint performance and high-intensity power output: improved; Sprint performance, peak power, total work output: improved; End-phase sprint capacity during prolonged exercise: improved |
| 42 Tam et al. 2025 | systematic review | Creatine supplementation; range of dosage strategies; 5 days to 12 weeks; vs. Placebo | anaerobic outcomes: improved (4/17 showed an improvement in anaerobic outcomes); aerobic outcomes: improved (1/5 showed an improvement in aerobic outcomes) |
Further studies in this area: 44 56 57 58 63 65 66 68 84 88 92 95 96 97 98 102 107 112 119 120 122 123 129 131 133 134 135 136 140 143 144 146 149 151 152 154 155 157 159 160 162 166 174 175 176 181 182 183 187 190 193 194 196 197 198 199 202 207 208 210 215 216 220 225 227 228 232 233 236 240 242 247 248 249 251 257 258 260 261 263 265 271 272 273 274 275 285 305 306 312 315 316 321 322 324 327 335 336 339 341 348 350 353 356 357 358
Creatine, Muscles and Bones in Older Age: Human Studies
In older people, creatine showed benefits for fat-free mass in several controlled trials and meta-analyses, mostly in combination with strength training 1416182260. Muscle mass also improved in individual studies and meta-analyses 70214. The sit-to-stand test was better under creatine in several controlled trials 922. A single randomized controlled trial also found better physical function 80. Bone findings are inconsistent: one randomized controlled trial found more bone mineral content in the arm 230, another a larger bone area in the shinbone 179. Several controlled trials and meta-analyses, by contrast, showed no difference in bone density 81630188191. No difference was found in bone mineral content or bone quality either in controlled trials 180188. Mostly creatine monohydrate was studied, usually with or without accompanying strength training. What remains open is the optimal dose, a possible loading phase, and whether the benefit extends to bones and fall risk over longer periods.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 8 Sharifian et al. 2025 | meta-analysis · 1,093 participants | Creatine supplementation plus exercise training; vs. Placebo plus exercise training | Bone mineral density of total body (g/cm2): no difference (mean difference = 0.009, Z = 0.587, P = 0.557) |
| 9 Davies et al. 2024 | meta-analysis · 1,076 participants | Creatine supplementation; vs. Placebo | Sit-to-stand test (physical function): improved (SMD 0.51 (95% CI: 0.01-1.00; I2 = 62%; P = 0.04)); Lean tissue mass: improved (MD 1.08 kg; 95% CI: 0.77-1.38; I2 = 26%; P < 0.01) |
| 10 Davies et al. 2023 | meta-analysis · 1,076 participants | Creatine supplementation; vs. Placebo | Sit-to-stand test (physical function): improved (SMD 0.51 (95% CI 0.01 to 1.00; I =62%; p=0.04)); Lean tissue mass: improved (MD 1.08kg; 95% CI 0.77 to 1.38; I =26%; p<0.01) |
| 13 Chen et al. 2026 | meta-analysis · 763 participants | Creatine monohydrate (3 studies) plus structured exercise; vs. Exercise alone or placebo plus exercise | Bone mineral content: no difference (g=0.195, 95% CI: -0.281 to 0.671, p=0.421); Bone mineral density: no difference (g=0.087, 95% CI: -0.129 to 0.303, p=0.430) |
| 14 Chilibeck et al. 2017 | meta-analysis · 721 participants | Creatine supplementation; 7-52 weeks; vs. Placebo during resistance training 2-3 days/week | Lean tissue mass: improved (mean difference =1.37 kg [95% CI =0.97-1.76]; p<0.00001) |
| 16 Naddafha et al. 2026 | systematic review · 608 participants | creatine monohydrate, with or without resistance training; ≥5 g/day effective; ≤3 g/day without RT no effect; 12-104 weeks, median 38 weeks; vs. placebo | Lean mass (DXA): improved (MD +0.37 kg (95% CI +0.05 to +0.69; I² = 25%)); Bone mineral density: no difference (unchanged overall) |
| 18 Liu et al. 2025 | systematic review · 482 participants | creatine plus resistance training (2–3 sessions/week); 8–104 weeks; vs. placebo plus resistance training | lean tissue mass: improved (SMD = 0.27 [95% CI 0.02–0.53]; p = 0.03); lean tissue mass (≤32 weeks): improved (SMD = 0.57 [95% CI 0.19–0.96]; p = 0.004) |
| 22 Devries et al. 2014 | meta-analysis · 357 participants | Creatine (form not stated in abstract); Resistance training 12.6 ± 4.9 weeks; vs. Creatine + resistance training vs. resistance training alone (placebo-controlled) | Total body mass: improved (P = 0.004); Fat-free mass: improved (P < 0.0001); Fat mass: no difference |
Further studies in this area: 30 38 43 47 53 60 64 68 70 80 106 117 122 134 153 167 178 179 180 184 188 191 200 205 211 214 230 252 307 308 309 310 313 318 319 323 328 331 332 333 337 338 345 346
Creatine, Memory and Brain: Human Studies
For memory and brain, the studies show a mixed picture: several meta-analyses found better memory performance after creatine monohydrate, in one of them especially in older adults 172454. Attention also improved in controlled trials 417, and processing speed in further ones 17253. Studies found no difference in overall cognition, executive function, and logical thinking 175279. One randomized controlled trial with creatine monohydrate added to escitalopram found more favorable neurochemical markers in women with major depression 85. It remains open which form, dose, and population actually benefit.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Marshall et al. 2026 | systematic review · 1,542 participants | Creatine monohydrate (in intervention studies) or estimated dietary creatine intake; vs. Not uniform; two double-blind intervention studies, four cross-sectional studies | Cognition (memory and attention): improved (Five of the six (83.3%) studies reported a positive relationship) |
| 17 Xu et al. 2024 | meta-analysis · 492 participants | creatine monohydrate; short <4 weeks vs. long ≥4 weeks; vs. placebo or control | memory: improved (SMD = 0.31, 95% CI: 0.18-0.44); attention time: improved (SMD = -0.31, 95% CI: -0.58 to -0.03); processing speed time: improved (SMD = -0.51, 95% CI: -1.01 to -0.01) |
| 24 Avgerinos et al. 2018 | systematic review · 281 participants | Oral creatine supplementation; vs. Placebo or control within the RCTs | short-term memory: improved; intelligence/reasoning: improved; long-term memory, spatial memory, attention, executive function and other cognitive domains: unclear |
| 33 Jeryous et al. 2026 | systematic review | Creatine monohydrate as adjunct treatment; 2 to 10 g/day; 4-8 weeks; vs. Placebo, added to SSRI, pharmacotherapy or psychotherapy | Correlation of brain N-acetylaspartate and phosphocreatine with improvement: improved |
| 39 Williams et al. 2026 | systematic review | Creatine supplementation | Cognitive outcomes: improved |
| 46 Xu et al. 2025 | systematic review | Creatine supplementation | Cognitive function: unclear |
| 51 McMorris et al. 2024 | systematic review | Creatine supplementation | Brain creatine content: improved; Cognition: unclear (somewhat equivocal results) |
| 52 EFSA et al. 2024 | systematic review | Creatine supplementation; 20 g/day, 2.2-14 g/day, 5 g/day; 5-7 days, 6 weeks after 5-day loading; vs. Lower doses, continuous intake, placebo/control; manufacturer-funded | Working memory: unclear (20 g/day for 5-7 days); Response inhibition: unclear (20 g/day for 7 days); Cognitive function overall: no difference |
Further studies in this area: 54 63 64 68 79 82 85 92 128 135 136 143 152 169 172 204 212 213 216 241 243 247 253 262 267 281 285 286 287 290 291 292 297 303 307 310 312 317 320 321 323 324 325 326 329 333 337 346 347 355
Creatine, Mood and Depression: Human Studies
In adults with depression, creatine monohydrate as an addition to cognitive behavioral therapy showed improvement in depression severity 158. Also as an addition to escitalopram, creatine monohydrate improved depressive symptoms in women with major depression 85. A systematic review found a decrease in depression severity and a higher remission rate, while treatment response did not differ 7. Another systematic review found creatine as an addition to escitalopram or cognitive behavioral therapy more effective than placebo, but not in adolescents or bipolar depression 33. In bipolar depression, a randomized controlled trial found no change in the MADRS score, but a higher remission rate 99. By contrast, a randomized controlled trial in physically active men found no difference in mood after a single dose 143. A randomized controlled trial with a combined preparation of creatine monohydrate, beta-alanine, L-taurine, L-leucine, and caffeine showed no change in mood states 122. A randomized controlled trial with creatine monohydrate plus maltodextrin found no difference in mood state 162. The findings come predominantly from small, short studies in specific patient groups; dose, loading phase, and training accompaniment were reported only partially, and transferability to broader populations remains open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 7 Eckert et al. 2025 | systematic review · 1,093 participants | Creatine supplementation; vs. Placebo | Depressive symptoms (SMD): improved (-0·34 (95 % CI -0·68, -0·00)); Remission: improved (OR 3·60; 95 % CI 1·76, 7·56); Treatment response: no difference (OR 0·72; 95 % CI 0·28, 1·88) |
| 33 Jeryous et al. 2026 | systematic review | Creatine monohydrate as adjunct treatment; 2 to 10 g/day; 4-8 weeks; vs. Placebo, added to SSRI, pharmacotherapy or psychotherapy | Depression severity in MDD (escitalopram + creatine vs SSRI + placebo): improved (Cohen's d = 1.13 at 8 weeks); Depression severity in MDD (pharmacotherapy augmentation in adolescents): no difference (no difference vs placebo); Depression severity in MDD (CBT + creatine vs CBT + placebo): improved |
| 39 Williams et al. 2026 | systematic review | Creatine supplementation | Mood: unclear |
| 85 Yoon et al. 2016 | randomised controlled · 52 participants | creatine monohydrate added to escitalopram; 8 weeks; vs. placebo added to escitalopram | improvement in depressive symptoms: improved |
| 99 Toniolo et al. 2018 | randomised controlled · 35 participants | Creatine monohydrate as adjunctive therapy; 6 g daily; 6 weeks; vs. Placebo added to regular medication | MADRS score change (ITT): no difference (p = 0.560; Cohen's d = 0.231); Remission (MADRS ≤ 12) at week 6, ITT: improved (52.9% remission in the creatine group vs. 11.1% remission in the placebo group); Remission (MADRS ≤ 12) at week 6, completers: improved (66.7% remission in the creatine group vs. 18.2% remission in the placebo group) |
| 122 Outlaw et al. 2014 | randomised controlled · 20 participants | Pre-workout blend with creatine monohydrate, beta-alanine, L-taurine, L-leucine, caffeine; 30 g supplement 30 minutes before training; 8 days supplementation and 4 resistance-training bouts; vs. Maltodextrin placebo | Mood states: no difference |
| 143 Ben et al. 2026 | randomised controlled · 11 participants | Creatine monohydrate or placebo; 0.1 g/kg body mass, single dose; Single dose per experimental condition; vs. Placebo, no supplement control, timing of ingestion | POMS: no difference |
| 152 Butchart et al. 2022 | randomised controlled · 8 participants | Creatine supplement (form not stated); 10 weeks; vs. Placebo plus supervised progressive resistance training | CES-D depression scale: improved (p = 0.045) |
Further studies in this area: 158 162 204 213 219 243 269 301 303 312 317 324 326 337 346 354
Creatine, Kidney Values and Tolerability: Human Studies
In this area, the studies predominantly show that creatine administration does not impair kidney function. Several controlled studies found no differences in kidney function 201257 and in kidney and liver function 1286138. Urine parameters also remained unchanged in several controlled studies 138185217266. Side effects were as common in systematic reviews and controlled studies as with placebo 1212180205. One meta-analysis found higher serum creatinine and a calculated lower filtration rate, but no difference on direct measurement 11217. Creatine monohydrate was predominantly investigated; with conjugated linoleic acid, plasma creatinine rose, while creatinine clearance remained unchanged 97. It remains open how long-term intake affects people with pre-existing kidney disease, since most studies ran in healthy individuals or small groups.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Kreider et al. 2025 | systematic review · 12,839 participants | Creatine, mostly creatine monohydrate; mean 0.166 g/kg/d (about 12.5 g/d); mean 64.7 days, studies up to 14 yrs; vs. Placebo (13,452 participants in 652 studies) | Overall prevalence of side effects (13.2% of studies in the PLA groups and 13.7% of studies in the Cr-supplemented groups); Total frequency of side effects among participants (PLA 4.21%, Cr 4.60%, p = 0.828); Gastrointestinal issues (study percentage): worsened (PLA 4.3%, Cr 4.9%, p < 0.001) |
| 2 Gonzalez et al. 2026 | systematic review · 12,800 participants | Creatine monohydrate; grouped into tertiles (low, moderate, high); grouped into tertiles (low, moderate, high); vs. Placebo | renal side effects |
| 11 de et al. 2026 | systematic review · 1,036 participants | Creatine supplementation; vs. Placebo | Serum creatinine: worsened (MD, 0.14 mg/dL; 95% CI 0.05-0.22; P = .002); GFR (creatinine-based): worsened (MD, -10.75 mL/min; 95% CI -17.48 to -4.02; P = .002); GFR (Cr-EDTA): no difference (MD, 5.89 mL/min; 95% CI -0.30 to 12.08; P = .06) |
| 12 de et al. 2020 | systematic review · 951 participants | Creatine monohydrate (oral); vs. Placebo or control (stratified by dosing regimen) | Total adverse events (risk ratio) (RR 1.24 (95% CI 0.51, 2.98)); Renal and hepatic function: no difference |
| 16 Naddafha et al. 2026 | systematic review · 608 participants | creatine monohydrate, with or without resistance training; ≥5 g/day effective; ≤3 g/day without RT no effect; 12-104 weeks, median 38 weeks; vs. placebo | Renal indices: no difference (unchanged) |
| 32 Mancini et al. 2022 | systematic review · 87 participants | Creatine supplementation; vs. Placebo, metformin, glibenclamide | Adverse effects (No major adverse effects were observed) |
| 34 Tsiaras et al. 2026 | meta-analysis | Creatine supplementation; Subgroups <1 month and >1 month; vs. Control group without creatine | Serum creatinine: worsened (MD = 0.13 mg/dL, 95% CI: 0.07 to 0.18, n=19); Urea: no difference (MD = -0.60 mg/dL; 95% CI: -2.15 to 0.96, n=12); estimated glomerular filtration rate: no difference (MD = -5.20 mL/min/1.73 m2; 95% CI: -15.00 to 4.60, n=8) |
| 40 Rubinchuk et al. 2026 | systematic review | Creatine monohydrate | Renal function: no difference (no consistent short-term safety signals) |
Further studies in this area: 48 64 78 86 97 98 101 109 116 118 130 134 138 143 147 150 155 157 159 180 185 188 189 201 203 204 205 209 217 223 235 257 266 273 281 282 285 291 293 294 306 313 316 346 348 349 350 361
Creatine: Further Outcomes in Studies
Many different outcome measures have been investigated in this field, and results are mixed. Several meta-analyses found a lower body fat percentage under creatine with strength training 81527; absolute fat mass did not differ 1527. Creatine and phosphocreatine levels in muscle rose more strongly than under placebo in several controlled trials 109110216, while in others phosphocreatine remained unchanged 101133201. Muscle soreness and pain decreased more strongly than under placebo in several controlled trials 89127146270, as did inflammatory markers such as TNF-α 80215. Overall certainty is high because numerous randomized controlled trials and meta-analyses exist. Mostly creatine monohydrate was studied, sometimes with a loading phase and training accompaniment. Which dosage and type of exercise are most beneficial for the individual outcomes remains open; in early Huntington's disease, creatine did not slow functional decline 77.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Kreider et al. 2025 | systematic review · 12,839 participants | Creatine, mostly creatine monohydrate; mean 0.166 g/kg/d (about 12.5 g/d); mean 64.7 days, studies up to 14 yrs; vs. Placebo (13,452 participants in 652 studies) | Multivariate analysis of 49 side effects (p = 0.340); Mention of creatine in 28.4 million adverse event reports (0.00072%) |
| 2 Gonzalez et al. 2026 | systematic review · 12,800 participants | Creatine monohydrate; grouped into tertiles (low, moderate, high); grouped into tertiles (low, moderate, high); vs. Placebo | gastrointestinal side effects; liver side effects; musculoskeletal side effects |
| 5 Wang et al. 2026 | meta-analysis · 1,211 participants | Creatine supplementation (compared with protein and omega-3); vs. Protein, omega-3 supplementation and control | Recovery outcomes (SMD): no difference |
| 8 Sharifian et al. 2025 | meta-analysis · 1,093 participants | Creatine supplementation plus exercise training; vs. Placebo plus exercise training | Fat percentage (%): improved (mean difference = -0.548, Z = -2.231, P = 0.026) |
| 12 de et al. 2020 | systematic review · 951 participants | Creatine monohydrate (oral); vs. Placebo or control (stratified by dosing regimen) | Gastrointestinal events (risk ratio): no difference (RR 1.09 (95% CI 0.53, 2.24)); Weight gain (mean difference): no difference (1.24 kg pre-intervention, (95% CI -0.34, 2.82)) |
| 15 Forbes et al. 2019 | meta-analysis · 609 participants | Creatine supplementation; vs. Placebo during resistance training | Body fat percentage: improved (0.55%, p = 0.04); Fat mass: no difference (~0.5 kg more fat mass, p = 0.13) |
| 19 Del et al. 2025 | systematic review · 463 participants | Creatine supplementation (CrS); vs. Creatine vs. placebo group or baseline | Body weight: no difference (three found no changes, while two reported increases); Lean body mass: no difference (differences were not significant); Fat mass: unclear (reductions, no changes, or mitigated increases) |
| 21 Huang et al. 2024 | meta-analysis · 361 participants | Creatine supplementation; vs. Placebo | Physiological response: no difference (SMD: 0.04, 95% CI: -0.16, 0.23; p = 0.71); Body composition: no difference (SMD: 0.18; 95% CI: -0.05, 0.41; p = 0.12) |
Further studies in this area: 25 27 28 31 32 33 35 36 37 39 40 41 44 49 50 56 57 59 61 62 63 66 68 71 72 73 74 75 76 77 78 79 80 81 83 84 86 88 89 90 91 92 93 94 95 97 98 99 100 101 103 104 105 108 109 110 111 113 114 116 117 118 119 120 121 122 123 125 126 127 130 131 132 133 134 135 136 138 139 141 142 143 146 147 148 149 150 152 153 154 155 156 157 158 159 160 162 163 164 165 167 168 169 170 171 173 175 176 177 178 181 182 184 186 190 195 196 197 199 201 202 203 206 208 210 211 212 214 215 216 221 222 223 224 226 229 231 232 234 235 236 237 238 239 240 243 244 245 246 250 251 254 255 256 257 259 262 264 265 266 268 269 270 272 273 275 276 277 278 279 280 281 283 284 285 286 287 288 289 290 291 292 293 294 295 297 298 299 300 302 304 305 310 312 313 314 316 321 324 326 327 332 335 336 340 342 343 344 345 347 348 351 352 354 357 358 359 361 362
4. How Is Creatine Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used creatine monohydrate, sometimes with a loading phase and maintenance dose, usually in combination with strength training. Buffered creatine monohydrate (Kre-Alkalyn) did not perform better than creatine monohydrate (Creapure) in the Wingate test 98. Combination products were tested less often: with HMB, some advantages for strength and anaerobic performance were seen 66; with conjugated linoleic acid, more strength and fat-free mass than with placebo 97.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| creatine monohydrate vs. placebo | 10 g/d | at least 5 years (maximum follow-up 8 years) | 71 |
| creatine monohydrate 10 g/day (parent trial intervention) | 10 gm/day | 1-6 years of longitudinal data | 72 |
| Creatine 3 g/day, partly with folic acid | 3 g creatine daily | 12 weeks | 73 |
| Creatine 3 g/day, partly with folic acid 400 µg/day | 3 g creatine per day | 24 weeks | 74 |
| Creatine 3 g/day, some with 400 µg folic acid | 3 g creatine daily | 24 weeks | 75 |
| Creatine (comparison arms: folic acid 400/800 µg/d, placebo) | 3 g/d creatine | 12 weeks | 76 |
| Creatine monohydrate | up to 40 g daily | up to 48 months | 77 |
| Oral creatine monohydrate | 10 g daily | average 310 days | 78 |
| creatine supplement | 5 g daily | 6 weeks per phase (cross-over) | 79 |
| Daily creatine plus high-load resistance training (elastic bands or water) or control | 3 g daily | 16 weeks | 80 |
| creatine monohydrate plus physical exercise | 5 g/day | 8 weeks | 81 |
| Creatine or placebo | — | 7 days | 82 |
| creatine supplement vs. placebo vs. control without supplement/exercise | 25 g/d for 5 days, then 5 g/d | 8 weeks | 83 |
| creatine monohydrate (CrMH) vs. carbohydrate drinks vs. placebo | 25 g CrMH daily for 5 days | 5 days | 84 |
| creatine monohydrate added to escitalopram | — | 8 weeks | 85 |
5. Is Creatine Safe? Side Effects in Studies
Several controlled studies and systematic reviews report tolerability comparable to placebo without differences in side effects 1212180. One meta-analysis found higher serum creatinine and a calculated lower filtration rate, but no difference on direct measurement 11217. In a large study in Huntington's disease, gastrointestinal complaints occurred more often with creatine than with placebo 77. In a cognition study, side effects were also more common with creatine 79.
| Study | Reported side effects |
|---|---|
| 1 Kreider et al. 2025 | Side effects in 13.7% creatine vs 13.2% placebo studies, no significant difference |
| 2 Gonzalez et al. 2026 | reported side effects infrequent, primarily mild and nonspecific |
| 11 de et al. 2026 | No kidney injury; creatinine and GFR changes reflect creatine metabolism |
| 12 de et al. 2020 | No deaths or serious adverse outcomes; no differences in total, GI events, weight, renal/hepatic |
| 13 Chen et al. 2026 | No increase in adverse events |
| 16 Naddafha et al. 2026 | mild and similar to placebo; renal indices unchanged |
| 19 Del et al. 2025 | CrS appears safe |
| 24 Avgerinos et al. 2018 | Creatine is described as safe |
| 26 Metzger et al. 2023 | No studies designed to address safety |
| 31 Salazar-Méndez et al. 2026 | No major adverse events reported |
| 32 Mancini et al. 2022 | No major adverse effects observed |
| 33 Jeryous et al. 2026 | Generally well tolerated; 2 of 17 participants had hypomania/mania |
6. What Remains Open: Limits of the Evidence
- Many studies were small and short, which limits the transferability of the results.
- The heterogeneity between populations, training protocols and dosages leaves open for whom and under what conditions the benefit is greatest.
- Long-term data in people with pre-existing kidney disease are still pending.
- The EFSA, on application by a manufacturer, saw no established cause-and-effect relationship between creatine and better cognitive function 52.
- The optimal dose, a possible loading phase and the transferability to bone and fall risk over longer periods remain open.
7. Bottom Line: What Is Established About Creatine
Creatine with strength training increased maximal strength and fat-free mass more than placebo in several meta-analyses 3, including in older people 1422. For sprint performance and memory, the results are mixed 215254131. Bone density remained unchanged in several controlled studies and meta-analyses 830188. Kidney function remained unchanged in several controlled studies 86201, and side effects were as common in reviews and studies as with placebo 112180. The evidence is strong, but many studies were small and short, and the heterogeneity between populations, training protocols and dosages leaves open for whom and under what conditions the benefit is greatest.
Frequently Asked Questions
How well has Creatine been studied in humans?
We evaluated 367 human studies on Creatine, including 165 randomised controlled trials and 70 meta-analyses or systematic reviews; the controlled studies include 8,940 participants in total. As of 3 October 2026.
Does Creatine help with strength and muscle mass? What the studies show
Does Creatine help with sprint and endurance performance? What the studies show
Does Creatine help with muscles and bones in older age? What the studies show
Does Creatine help with memory and brain? What the studies show
Does Creatine help with mood and depression? What the studies show
Does Creatine help with kidney values and tolerability? What the studies show
Which form of creatine was investigated in the studies?
The studies predominantly used creatine monohydrate, sometimes with a loading phase and maintenance dose, usually in combination with strength training. Buffered creatine monohydrate (Kre-Alkalyn) did not perform better than creatine monohydrate (Creapure) in the Wingate test 98. Combination products were tested less often: with HMB, some advantages for strength and anaerobic performance were seen 66; with conjugated linoleic acid, more strength and fat-free mass than with placebo 97.
How safe is creatine for the kidneys?
Which side effects were reported?
Tolerability was comparable to placebo in several controlled studies and systematic reviews, without differences in side effects 1212180. In a large study in Huntington's disease, gastrointestinal complaints occurred more often with creatine than with placebo 77. In a cognition study, side effects were also more common with creatine 79. In one study, significant weight gain was reported in the creatine group 84.
Does creatine show an effect in older people?
Is there evidence of benefits for the brain?
Several meta-analyses found better memory performance after creatine monohydrate, in one of them especially in older adults 172454. Attention also improved in controlled studies 417, and processing speed in further studies 17253. Studies found no difference in overall cognition, executive function and logical reasoning 175279. The EFSA, on application by a manufacturer, saw no established cause-and-effect relationship between creatine and better cognitive function 52.
Sources
- 1Kreider RB, Gonzalez DE, Hines K, Gil A, Bonilla DA · 2025
- 2Gonzalez DE, Dickerson BL, Hines K, Chun J, Gil A, Forbes SC et al. · 2026
- 3Kazeminasab F, Kerchi AB, Sharafifard F, Zarreh M, Forbes SC, Camera DM et al. · 2025
- 4Marshall S, Kitzan A, Wright J, Bocicariu L, Nagamatsu LS · 2026
- 5
- 6Delpino FM, Figueiredo LM, Forbes SC, Candow DG, Santos HO · 2022
- 7Eckert I, Lima J, Dariva AA · 2025
- 8Sharifian G, Aseminia P, Heidary D, Esformes JI · 2025
- 9Davies TW, Watson N, Pilkington JJ, McClelland TJ, Azzopardi G, Pearse RM et al. · 2024
- 10Davies T, Watson N, Pilkington J, McClelland T, Azzopardi G, Pearse R et al. · 2023
- 11de Souza Almeida A, da Silva LOD, Takahasi BNA, Terada BD, Gonçalves FGA, Porto BC et al. · 2026
- 12de Guingand DL, Palmer KR, Snow RJ, Davies-Tuck ML, Ellery SJ · 2020
- 13Chen KH, Yeh TP, Lin SC, Liu PJ, Bai D, Chen IH · 2026
- 14Chilibeck PD, Kaviani M, Candow DG, Zello GA · 2017
- 15Forbes SC, Candow DG, Krentz JR, Roberts MD, Young KC · 2019
- 16Naddafha S, Antonio J, Kreider RB, Stout JR · 2026
- 17Xu C, Bi S, Zhang W, Luo L · 2024
- 18Liu S, Huang N, Wu W, OuYang X, Luo Y, Zhong Y et al. · 2025
- 19Del Arco A, Aguirre-Elordui S, Olasagasti-Ibargoien J, Castañeda-Babarro A · 2025
- 20Gras D, Lanhers C, Bagheri R, Ugbolue UC, Coudeyre E, Pereira B et al. · 2023
- 21Huang D, Wang X, Gonjo T, Takagi H, Huang B, Huang W et al. · 2024
- 22Devries MC, Phillips SM · 2014
- 23Aguinaga-Ontoso I, Guillen-Aguinaga S, Guillen-Aguinaga L, Alas-Brun R, Guillen-Grima F · 2023
- 24Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D · 2018
- 25
- 26Metzger GA, Minneci PM, Gehred A, Day A, Klingele KE · 2023
- 27Candow DG, Prokopidis K, Forbes SC, Rusterholz F, Campbell BI, Ostojic SM · 2023
- 28Prokopidis K, Forbes S, Candow DG, Rusterholz F, Campbell B, Ostojic S · 2023
- 29Dos Santos EEP, de Araújo RC, Candow DG, Forbes SC, Guijo JA, de Almeida Santana CC et al. · 2021
- 30Forbes SC, Chilibeck PD, Candow DG · 2018
- 31Salazar-Méndez J, Núñez-Cortés R, Salazar-Orellana C, Suso-Martí L, Calatayud J, Cuyul-Vásquez I et al. · 2026
- 32Mancini de Sousa M, Nakata MTK, Baldini CES, de Oliveira-Sales EB, Boim MA, Martimbianco ALC et al. · 2022
- 33Jeryous Fares B, Zhou C, Fabiano N, Wong S, Stubbs B, Shorr R et al. · 2026
- 34Tsiaras A, Loufopoulos G, Theodoridis X, Liakopoulos V, Poulia KA, Chourdakis M · 2026
- 35Gimenez FVM, Pasternak N, Santesso L, da Silva LMA, Girotto LA, Candeloro BM et al. · 2026
- 36Bučević Popović V, Sovulj A, Raić S, Pezelj I, Bala MM, Puljak L · 2026
- 37Wesołowski I, Dzienisiewicz J, Langa D, Ziółkowski W, Karbowska J, Kochan Z · 2026
- 38
- 39Williams NB, Hurley RB, Cevallos ME · 2026
- 40Rubinchuk A, Dulkoski Z, Persaud NA, Wallen M · 2026
- 41Ashtary-Larky D, Mohammadi S, Hajizadeh L, Mousavi SAH, Forbes SC, Candow DG et al. · 2025
- 42Tam R, Mitchell L, Forsyth A · 2025
- 43Zhang H, Lan T, Yan X, Gu H, Li Y, He E · 2025
- 44Ashtary-Larky D, Candow DG, Forbes SC, Hajizadeh L, Peacock CA, Kalman D et al. · 2025
- 45Ma Y, Yan R, Li Y, Li D, Sun X, Chen T et al. · 2025
- 46Xu C, Bi S, Zhang W, Luo L · 2025
- 47Andrea P, Irene S, Maurizio B · 2025
- 48Naeini EK, Eskandari M, Mortazavi M, Gholaminejad A, Karevan N · 2025
- 49Pashayee-Khamene F, Heidari Z, Asbaghi O, Ashtary-Larky D, Goudarzi K, Forbes SC et al. · 2024
- 50Desai I, Wewege MA, Jones MD, Clifford BK, Pandit A, Kaakoush NO et al. · 2024
- 51McMorris T, Hale BJ, Pine BS, Williams TB · 2024
- 52EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J et al. · 2024
- 53Burke R, Piñero A, Coleman M, Mohan A, Sapuppo M, Augustin F et al. · 2023
- 54Prokopidis K, Giannos P, Triantafyllidis KK, Kechagias KS, Forbes SC, Candow DG · 2023
- 55Wu SH, Chen KL, Hsu C, Chen HC, Chen JY, Yu SY et al. · 2022
- 56Glaister M, Rhodes L · 2022
- 57
- 58Bauermann A, de Sá KSG, Santos ZA, Costa E Silva AA · 2022
- 59Doma K, Ramachandran AK, Boullosa D, Connor J · 2022
- 60Forbes SC, Candow DG, Ostojic SM, Roberts MD, Chilibeck PD · 2021
- 61
- 62Kreider RB, Stout JR · 2021
- 63Kaviani M, Shaw K, Chilibeck PD · 2020
- 64
- 65Mielgo-Ayuso J, Calleja-Gonzalez J, Marqués-Jiménez D, Caballero-García A, Córdova A, Fernández-Lázaro D · 2019
- 66Fernández-Landa J, Calleja-González J, León-Guereño P, Caballero-García A, Córdova A, Mielgo-Ayuso J · 2019
- 67Lanhers C, Pereira B, Naughton G, Trousselard M, Lesage FX, Dutheil F · 2017
- 68Havenetidis K · 2016
- 69Lanhers C, Pereira B, Naughton G, Trousselard M, Lesage FX, Dutheil F · 2015
- 70Candow DG, Chilibeck PD, Forbes SC · 2014
- 71Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R et al. · 2015
- 72Wills AM, Li R, Pérez A, Ren X, Boyd J, NINDS NET-PD Investigators · 2017
- 73Bozack AK, Howe CG, Hall MN, Liu X, Slavkovich V, Ilievski V et al. · 2021
- 74Bozack AK, Hall MN, Liu X, Ilievski V, Lomax-Luu AM, Parvez F et al. · 2019
- 75Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A et al. · 2015
- 76Hall MN, Howe CG, Liu X, Caudill MA, Malysheva O, Ilievski V et al. · 2016
- 77Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R et al. · 2017
- 78Groeneveld GJ, Beijer C, Veldink JH, Kalmijn S, Wokke JH, van den Berg LH · 2005
- 79Sandkühler JF, Kersting X, Faust A, Königs EK, Altman G, Ettinger U et al. · 2023
- 80Fernandez-Garrido J, Martin EG, Saez-Berlanga A, Gargallo-Bayo P, Gene-Morales J, Alix-Fages C et al. · 2026
- 81Hemati F, Rahmani A, Asadollahi K, Soleimannejad K, Khalighi Z · 2016
- 82Merege-Filho CA, Otaduy MC, de Sá-Pinto AL, de Oliveira MO, de Souza Gonçalves L, Hayashi AP et al. · 2017
- 83Creatine supplementation alters homocysteine level in resistance trained menBereket-Yücel S · 2015
- 84Koenig CA, Benardot D, Cody M, Thompson WR · 2008
- 85Yoon S, Kim JE, Hwang J, Kim TS, Kang HJ, Namgung E et al. · 2016
- 86Ferreira AB, Pinto LCC, Taira NMU, Batista VCS, Matuoka CSL, Pinheiro LDF et al. · 2026
- 87Nunes JP, Ribeiro AS, Schoenfeld BJ, Tomeleri CM, Avelar A, Trindade MC et al. · 2017
- 88Glaister M, Lockey RA, Abraham CS, Staerck A, Goodwin JE, McInnes G · 2006
- 89Osama M, Afridi S, Bonnechère B · 2025
- 90Yamaguchi S, Inami T, Nishioka T, Morito A, Ishiyama K, Murayama M · 2025
- 91Pohl F, Dominique A, Dufour J, Wang J, Lin XL, Sharif B et al. · 2025
- 92
- 93Wilkinson TJ, Lemmey AB, Jones JG, Sheikh F, Ahmad YA, Chitale S et al. · 2016
- 94Sakkas GK, Mulligan K, Dasilva M, Doyle JW, Khatami H, Schleich T et al. · 2009
- 95Hoffman JR, Stout JR, Falvo MJ, Kang J, Ratamess NA · 2005
- 96Gordon AN, Moore SR, Patterson ND, Hostetter ME, Cabre HE, Hirsch KR et al. · 2023
- 97Tarnopolsky M, Zimmer A, Paikin J, Safdar A, Safdar A, Aboud A et al. · 2007
- 98Jagim AR, Oliver JM, Sanchez A, Galvan E, Fluckey J, Riechman S et al. · 2012
- 99Toniolo RA, Silva M, Fernandes FBF, Amaral JAMS, Dias RDS, Lafer B · 2018
- 100Dinan NE, Hagele AM, Jagim AR, Miller MG, Kerksick CM · 2022
- 101Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ · 2004
- 102Anders JPV, Neltner TJ, Smith RW, Keller JL, Housh TJ, Daugherty FJ et al. · 2021
- 103Banerjee B, Sharma U, Balasubramanian K, Kalaivani M, Kalra V, Jagannathan NR · 2010
- 104Trehan A, Anand R, Kumari P, Singh H, Soni N, Madan R et al. · 2025
- 105Rahimi R, Mirzaei B, Rahmani-Nia F, Salehi Z · 2015
- 106Ramos-Hernández R, Miguel-Ortega Á, Martínez-Ferrán M, Fernández-Lázaro D, Busto N, Mielgo-Ayuso J · 2026
- 107Fairman CM, Kendall KL, Newton RU, Hart NH, Taaffe DR, Lopez P et al. · 2025
- 108Backx EMP, Hangelbroek R, Snijders T, Verscheijden ML, Verdijk LB, de Groot LCPGM et al. · 2017
- 109Spillane M, Schoch R, Cooke M, Harvey T, Greenwood M, Kreider R et al. · 2009
- 110Askow AT, Paulussen KJM, McKenna CF, Salvador AF, Scaroni SE, Hamann JS et al. · 2022
- 111Fernández-Landa J, Fernández-Lázaro D, Calleja-González J, Caballero-García A, Córdova A, León-Guereño P et al. · 2020
- 112Fernández-Landa J, Fernández-Lázaro D, Calleja-González J, Caballero-García A, Córdova Martínez A, León-Guereño P et al. · 2020
- 113Fairman CM, Brooks AM, Candow DG, Jackson KE, Bottone G, Scott B et al. · 2026
- 114Effect of creatine supplementation on muscle damage and repair following eccentrically-induced damage to the elbow flexor musclesMcKinnon NB, Graham MT, Tiidus PM · 2012
- 115Wageh M, Fortino SA, McGlory C, Kumbhare D, Phillips SM, Parise G · 2021
- 116Percário S, Domingues SP, Teixeira LF, Vieira JL, de Vasconcelos F, Ciarrocchi DM et al. · 2012
- 117Todorovic N, Nedeljkovic D, Korovljev D, Stajer V, Prémusz V, Ács P et al. · 2026
- 118Wagner JC, Faulkner M, Faulkner W, Mullins F · 2025
- 119Barranco-Gil D, Alejo LB, Revuelta C, Górriz M, Pagola I, Ozcoidi LM et al. · 2024
- 120Zuniga JM, Housh TJ, Camic CL, Hendrix CR, Mielke M, Johnson GO et al. · 2012
- 121Cooke MB, Brabham B, Buford TW, Shelmadine BD, McPheeters M, Hudson GM et al. · 2014
- 122Outlaw JJ, Wilborn CD, Smith-Ryan AE, Hayward SE, Urbina SL, Taylor LW et al. · 2014
- 123Hass CJ, Collins MA, Juncos JL · 2007
- 124Parsowith EJ, Stock MS, Kocuba O, Schumpp A, Jackson K, Brooks AM et al. · 2024
- 125Taylor BA, Panza G, Ballard KD, White CM, Thompson PD · 2018
- 126
- 127Creatine Supplementation Supports the Rehabilitation of Adolescent Fin Swimmers in Tendon Overuse Injury CasesJuhasz I, Kopkane JP, Hajdu P, Szalay G, Kopper B, Tihanyi J · 2018
- 128Toniolo RA, Fernandes FBF, Silva M, Dias RDS, Lafer B · 2017
- 129Gonzalez AM, Pinzone AG, Bram J, Salisbury JL, Lee S, Mangine GT · 2020
- 130Doorenbos CSE, van der Veen Y, Post A, Jonker J, Knobbe TJ, Kremer D et al. · 2026
- 131Bogdanis GC, Nevill ME, Aphamis G, Stavrinou PS, Jenkins DG, Giannaki CD et al. · 2022
- 132Nedeljkovic D, Todorovic N, Javorac D, Baltic S, Vranes M, Panic J et al. · 2026
- 133Bonne TC, Arthemalle V, Doherty CS, Andersen AB, Bejder J, Ehlers T et al. · 2025
- 134Hayashi AP, Solis MY, Sapienza MT, Otaduy MC, de Sá Pinto AL, Silva CA et al. · 2014
- 135Ben Maaoui K, Delleli S, Mahdi N, Jebabli A, Del Coso J, Chtourou H et al. · 2025
- 136Semeredi S, Stajer V, Ostojic J, Vranes M, Ostojic SM · 2019
- 137Claudino JG, Mezêncio B, Amaral S, Zanetti V, Benatti F, Roschel H et al. · 2014
- 138Cancela P, Ohanian C, Cuitiño E, Hackney AC · 2008
- 139Slankamenac J, Ranisavljev M, Todorovic N, Ostojic J, Stajer V, Ostojic SM · 2023
- 140Lamontagne-Lacasse M, Nadon R, Goulet E DB · 2011
- 141Safdar A, Safdar A, Yardley NJ, Snow R, Melov S, Tarnopolsky MA · 2008
- 142Creatine use and exercise heat tolerance in dehydrated menWatson G, Casa DJ, Fiala KA, Hile A, Roti MW, Healey JC et al. · 2006
- 143Ben Maaoui K, Delleli S, Jebabli A, Mahdi N, Del Coso J, Chtourou H et al. · 2026
- 144Feuerbacher JF, von Schöning V, Melcher J, Notbohm HL, Freitag N, Schumann M · 2021
- 145Vieira IP, de Paula AG, Gentil P, Pichard C, Candow DG, Pimentel GD · 2020
- 146Salem A, Ammar A, Kerkeni M, Boujelbane MA, Merve Uyar A, Moritz Köbel L et al. · 2025
- 147
- 148Hone M, Kent RM, Scotto di Palumbo A, Bleiel SB, De Vito G, Egan B · 2017
- 149Oliver JM, Jagim AR, Pischel I, Jäger R, Purpura M, Sanchez A et al. · 2014
- 150Chang CT, Wu CH, Yang CW, Huang JY, Wu MS · 2002
- 151Griffen C, Rogerson D, Ranchordas M, Ruddock A · 2015
- 152Butchart S, Candow DG, Forbes SC, Mang CS, Gordon JJ, Ko J et al. · 2022
- 153Ramos-Hernández R, Busto N, Miguel-Ortega Á, Martínez-Ferrán M, Santamaría-Peláez M, Saiz-Rodríguez M et al. · 2026
- 154Wang Y, Wei H, Cheng X, Chen Z · 2026
- 155López-Moreno M, Muñoz A, Aguilar-Navarro M, Gutiérrez-Hellín J, Franco-Andrés A, López-López P et al. · 2026
- 156Dos Santos MSC, Dorna MS, Costa AF, Franco EAT, Bassani I, Geronutti J et al. · 2026
- 157
- 158Sherpa NN, De Giorgi R, Ostinelli EG, Choudhury A, Dolma T, Dorjee S · 2025
- 159Woodcock IR, de Valle K, Cairns A, Davidson ZE, Kean M, Varma N et al. · 2025
- 160Salem A, Ammar A, Kerkeni M, Ali Boujelbane M, Merve Uyar A, Moritz Köbel L et al. · 2025
- 161Huerta Ojeda Á, Jofré-Saldía E, Torres-Banduc M, Galdames Maliqueo S, Barahona-Fuentes G, Cofré Acevedo C et al. · 2024
- 162Furtado ETF, Oliveira JPL, Pereira ISB, Veiga EP, Silva SFD, Abreu WC · 2024
- 163Yamaguchi S, Inami T, Ishida H, Morito A, Yamada S, Nagata N et al. · 2024
- 164Aguiar Bonfim Cruz AJ, Brooks SJ, Kleinkopf K, Brush CJ, Irwin GL, Schwartz MG et al. · 2024
- 165Aron A, Landrum EJ, Schneider AD, Via M, Evans L, Rawson ES · 2024
- 166Moesgaard L, Jessen S, Christensen PM, Bangsbo J, Hostrup M · 2024
- 167Souza JT, Minicucci MF, Ferreira NC, Polegato BF, Okoshi MP, Modolo GP et al. · 2024
- 168Clarke HE, Akhavan NS, Behl TA, Ormsbee MJ, Hickner RC · 2024
- 169Slankamenac J, Ranisavljev M, Todorovic N, Ostojic J, Stajer V, Candow DG et al. · 2024
- 170
- 171Moore SR, Gordon AN, Cabre HE, Hackney AC, Smith-Ryan AE · 2023
- 172Moriarty T, Bourbeau K, Dorman K, Runyon L, Glaser N, Brandt J et al. · 2023
- 173Brooks SJ, Candow DG, Roe AJ, Fehrenkamp BD, Wilk VC, Bailey JP et al. · 2023
- 174Sousa-Silva R, Cholewa JM, Pessôa KA, Xia Z, Lauver JD, Rossi FE et al. · 2023
- 175Maicas-Pérez L, Hernández-Lougedo J, Heredia-Elvar JR, Pedauyé-Rueda B, Cañuelo-Márquez AM, Barba-Ruiz M et al. · 2023
- 176Pakulak A, Candow DG, Totosy de Zepetnek J, Forbes SC, Basta D · 2022
- 177The Effect of 4-Week Creatine Supplementation on Lipid Profile in Older Adults· 2022
- 178Roschel H, Hayashi AP, Fernandes AL, Jambassi-Filho JC, Hevia-Larraín V, de Capitani M et al. · 2021
- 179Candow DG, Chilibeck PD, Gordon JJ, Kontulainen S · 2021
- 180Candow DG, Chilibeck PD, Gordon J, Vogt E, Landeryou T, Kaviani M et al. · 2021
- 181Dover S, Stephens S, Schneiderman JE, Pullenayegum E, Wells GD, Levy DM et al. · 2021
- 182Domingues WJR, Ritti-Dias RM, Cucato GG, Wolosker N, Zerati AE, Puech-Leão P et al. · 2021
- 183
- 184Marini ACB, Motobu RD, Freitas ATV, Mota JF, Wall BT, Pichard C et al. · 2020
- 185Domingues WJR, Ritti-Dias RM, Cucato GG, Wolosker N, Zerati AE, Puech-Leão P et al. · 2020
- 186Oliveira CLP, Antunes BMM, Gomes AC, Lira FS, Pimentel GD, Boulé NG et al. · 2020
- 187Mills S, Candow DG, Forbes SC, Neary JP, Ormsbee MJ, Antonio J · 2020
- 188Sales LP, Pinto AJ, Rodrigues SF, Alvarenga JC, Gonçalves N, Sampaio-Barros MM et al. · 2020
- 189de Oliveira Vilar Neto J, da Silva CA, Meneses GC, Pinto DV, Brito LC, da Cruz Fonseca SG et al. · 2020
- 190Abdalla LHP, Broxterman RM, Greco CC, Denadai BS · 2020
- 191Candow DG, Forbes SC, Vogt E · 2019
- 192Chami J, Candow DG · 2019
- 193Bernat P, Candow DG, Gryzb K, Butchart S, Schoenfeld BJ, Bruno P · 2019
- 194Hummer E, Suprak DN, Buddhadev HH, Brilla L, San Juan JG · 2019
- 195Blancquaert L, Baguet A, Bex T, Volkaert A, Everaert I, Delanghe J et al. · 2018
- 196
- 197De Benedetto F, Pastorelli R, Ferrario M, de Blasio F, Marinari S, Brunelli L et al. · 2018
- 198Yáñez-Silva A, Buzzachera CF, Piçarro IDC, Januario RSB, Ferreira LHB, McAnulty SR et al. · 2017
- 199Johannsmeyer S, Candow DG, Brahms CM, Michel D, Zello GA · 2016
- 200Pinto CL, Botelho PB, Carneiro JA, Mota JF · 2016
- 201Solis MY, Hayashi AP, Artioli GG, Roschel H, Sapienza MT, Otaduy MC et al. · 2016
- 202Boychuk KE, Lanovaz JL, Krentz JR, Lishchynsky JT, Candow DG, Farthing JP · 2016
- 203Effects of creatine supplementation along with resistance training on urinary formaldehyde and serum enzymes in wrestlersNasseri A, Jafari A · 2016
- 204Kondo DG, Forrest LN, Shi X, Sung YH, Hellem TL, Huber RS et al. · 2016
- 205Lobo DM, Tritto AC, da Silva LR, de Oliveira PB, Benatti FB, Roschel H et al. · 2015
- 206Candow DG, Vogt E, Johannsmeyer S, Forbes SC, Farthing JP · 2015
- 207The effects of beta alanine plus creatine administration on performance during repeated bouts of supramaximal exercise in sedentary menOkudan N, Belviranli M, Pepe H, Gökbel H · 2015
- 208Camic CL, Housh TJ, Zuniga JM, Traylor DA, Bergstrom HC, Schmidt RJ et al. · 2014
- 209Candow DG, Zello GA, Ling B, Farthing JP, Chilibeck PD, McLeod K et al. · 2014
- 210Kresta JY, Oliver JM, Jagim AR, Fluckey J, Riechman S, Kelly K et al. · 2014
- 211Gualano B, Macedo AR, Alves CR, Roschel H, Benatti FB, Takayama L et al. · 2014
- 212Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP et al. · 2014
- 213Alves CR, Merege Filho CA, Benatti FB, Brucki S, Pereira RM, de Sá Pinto AL et al. · 2013
- 214Aguiar AF, Januário RS, Junior RP, Gerage AM, Pina FL, do Nascimento MA et al. · 2013
- 215Deminice R, Rosa FT, Franco GS, Jordao AA, de Freitas EC · 2013
- 216Alves CR, Santiago BM, Lima FR, Otaduy MC, Calich AL, Tritto AC et al. · 2013
- 217Lugaresi R, Leme M, de Salles Painelli V, Murai IH, Roschel H, Sapienza MT et al. · 2013
- 218Lowery RP, Joy JM, Dudeck JE, Oliveira de Souza E, McCleary SA, Wells S et al. · 2013
- 219Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W et al. · 2012
- 220Carvalho AP, Rassi S, Fontana KE, Correa Kde S, Feitosa RH · 2012
- 221Freilinger M, Dunkler D, Lanator I, Item CB, Mühl A, Fowler B et al. · 2011
- 222Gualano B, Lugaresi R, de Salles Painelli V, Queiroz AC, Artioli G, Roschel H et al. · 2011
- 223Cornish SM, Candow DG, Jantz NT, Chilibeck PD, Little JP, Forbes S et al. · 2009
- 224Kerksick CM, Wilborn CD, Campbell WI, Harvey TM, Marcello BM, Roberts MD et al. · 2009
- 225Herda TJ, Beck TW, Ryan ED, Smith AE, Walter AA, Hartman MJ et al. · 2009
- 226Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A et al. · 2008
- 227Zoeller RF, Stout JR, O'kroy JA, Torok DJ, Mielke M · 2007
- 228Stout JR, Cramer JT, Mielke M, O'Kroy J, Torok DJ, Zoeller RF · 2006
- 229Roy BD, de Beer J, Harvey D, Tarnopolsky MA · 2005
- 230Creatine monohydrate and resistance training increase bone mineral content and density in older menChilibeck PD, Chrusch MJ, Chad KE, Shawn Davison K, Burke DG · 2005
- 231Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD et al. · 2004
- 232Javierre C, Barbany JR, Bonjorn VM, Lizárraga MA, Ventura JL, Segura R · 2004
- 233Lehmkuhl M, Malone M, Justice B, Trone G, Pistilli E, Vinci D et al. · 2003
- 234Lambert CP, Archer RL, Carrithers JA, Fink WJ, Evans WJ, Trappe TA · 2003
- 235Walter MC, Reilich P, Lochmüller H, Kohnen R, Schlotter B, Hautmann H et al. · 2002
- 236Douligeris A, Methenitis S, Lazou A, Panayiotou G, Feidantsis K, Voulgaridou G et al. · 2023
- 237Wang CC, Fang CC, Lee YH, Yang MT, Chan KH · 2018
- 238Lukaszuk JM, Robertson RJ, Arch JE, Moyna NM · 2005
- 239van der Merwe J, Brooks NE, Myburgh KH · 2009
- 240Kingsley M, Cunningham D, Mason L, Kilduff LP, McEneny J · 2009
- 241Wilkinson ID, Mitchel N, Breivik S, Greenwood P, Griffiths PD, Winter EM et al. · 2006
- 242Willems ME, Sallis CW, Haskell JA · 2012
- 243VAN Cutsem J, Roelands B, Pluym B, Tassignon B, Verschueren JO, DE Pauw K et al. · 2020
- 244
- 245Pereira RT, Dörr FA, Pinto E, Solis MY, Artioli GG, Fernandes AL et al. · 2015
- 246Pilot Study: The Effect of Acute 5-Day Creatine Supplementation on Macrovascular Endothelial Function in Older AdultsClarke H, Kim D, Meza C, Hickner R · 2020
- 247Silva JV, Nunes Oliveira T, Sampaio P, de Sousa Sá OM, Barreto G, Roschel H et al. · 2026
- 248Meixner B, Stegmaier J, Renner P, Koehler K, Yang WH, Sperlich B · 2025
- 249Roberts TD, Arnett JE, Ortega DG, Pioske JS, Daugherty FJ, Tempesta MS et al. · 2025
- 250Marini ACB, Schincaglia RM, Candow DG, Pimentel GD · 2024
- 251Slankamenac J, Ranisavljev M, Todorovic N, Ostojic J, Stajer V, Ostojic SM · 2024
- 252Diaz-Pizarro M, Pino-Zúñiga J, Gálvez MO, Vesga CR, Tello RL, Seguro JCD et al. · 2024
- 253Gordji-Nejad A, Matusch A, Kleedörfer S, Jayeshkumar Patel H, Drzezga A, Elmenhorst D et al. · 2024
- 254Buck EA, Saunders MJ, Edwards ES, Womack CJ · 2023
- 255Fry AC, Parra ME, Cabarkapa D · 2021
- 256Ribeiro AS, Avelar A, Kassiano W, Nunes JP, Schoenfeld BJ, Aguiar AF et al. · 2020
- 257Creatine supplementation improves performance, but is it safe? Double-blind placebo-controlled studyAlmeida D, Colombini A, Machado M · 2020
- 258Soares Freitas Sampaio CR, Aidar FJ, Ferreira ARP, Santos JLD, Marçal AC, Matos DG et al. · 2020
- 259Van Bavel D, de Moraes R, Tibirica E · 2019
- 260de Poli RAB, Roncada LH, Malta ES, Artioli GG, Bertuzzi R, Zagatto AM · 2019
- 261Wang CC, Lin SC, Hsu SC, Yang MT, Chan KH · 2017
- 262Solis MY, Artioli GG, Otaduy MCG, Leite CDC, Arruda W, Veiga RR et al. · 2017
- 263Wang CC, Yang MT, Lu KH, Chan KH · 2016
- 264Effects of a High Protein and Omega-3-Enriched Diet with or Without Creatine Supplementation on Markers of Soreness and Inflammation During 5 Consecutive Days of High Volume Resistance Exercise in FemalesHayward S, Wilborn CD, Taylor LW, Urbina SL, Outlaw JJ, Foster CA et al. · 2016
- 265Ziegenfuss TN, Habowski SM, Lemieux R, Sandrock JE, Kedia AW, Kerksick CM et al. · 2015
- 266The effects of creatine supplementation on thermoregulation and isokinetic muscular performance following acute (3-day) supplementationRosene JM, Matthews TD, Mcbride KJ, Galla A, Haun M, Mcdonald K et al. · 2015
- 267Turner CE, Russell BR, Gant N · 2015
- 268Deminice R, Rosa FT, Franco GS, da Cunha SF, de Freitas EC, Jordao AA · 2014
- 269
- 270Veggi K FT, Machado M, Koch AJ, Santana SC, Oliveira SS, Stec MJ · 2013
- 271Barber JJ, McDermott AY, McGaughey KJ, Olmstead JD, Hagobian TA · 2013
- 272Barros MP, Ganini D, Lorenço-Lima L, Soares CO, Pereira B, Bechara EJ et al. · 2012
- 273Effects of Combined Creatine Plus Fenugreek Extract vs. Creatine Plus Carbohydrate Supplementation on Resistance Training AdaptationsTaylor L, Poole C, Pena E, Lewing M, Kreider R, Foster C et al. · 2011
- 274
- 275The use of varying creatine regimens on sprint cyclingHavenetidis K, Matsouka O, Cooke CB, Theodorou A · 2003
- 276Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K et al. · 2003
- 277Kutz MR, Gunter MJ · 2003
- 278Ostojic SM, Grasaas E · 2025
- 279Jiang J, Zhao H, Chen J, Du J, Ni W, Zheng B et al. · 2024
- 280Ostojic SM, Kavecan I · 2025
- 281Burridge J, Boolani A, Zhang Z, Glenn JM · 2026
- 282Zhou B, Hong M, Jin L, Ling K · 2024
- 283Nagy SR, Mititelu M, Popovici V, Bontea MG, Pallag A, Jurca T · 2025
- 284Leader A, Amital D, Rubinow A, Amital H · 2009
- 285[A clinical trial of creatine monohydrate in muscular dystrophy patients]Matsumura T, Yokoe M, Nakamori M, Hattori N, Saito T, Nozaki S et al. · 2004
- 286K Taylor M, Smith AN, Choi IY, Lee P, Kelly E, Arora T et al. · 2026
- 287Smith AN, Choi IY, Lee P, Sullivan DK, Burns JM, Swerdlow RH et al. · 2025
- 288Smith AN, Sullivan DK, Morris JK, Carbuhn AF, Herda TJ, Taylor MK · 2025
- 289Watson P, Judkins C, Houghton E, Russell C, Maughan RJ · 2009
- 290Stockler-Ipsiroglu S, Apatean D, Battini R, DeBrosse S, Dessoffy K, Edvardson S et al. · 2015
- 291Godlewska BR, Sylvester AL, Emir UE, Sharpley AL, Clarke WT, Martens MAG et al. · 2024
- 292Passi GR, Pandey S, Devi ARR, Konanki R, Jain AR, Bhatnagar S et al. · 2022
- 293Wagner JC, Ostojic S, Faulkner W, Faulkner M · 2026
- 294Sale C, Harris RC, Florance J, Kumps A, Sanvura R, Poortmans JR · 2009
- 295Ji Z, Zheng H, Yang Y, Li D, Li Z, Guo X · 2026
- 296Finezilber Y, Massey C, Radley JA, Murphy E · 2024
- 297Ndika JD, Johnston K, Barkovich JA, Wirt MD, O'Neill P, Betsalel OT et al. · 2012
- 298Xie S, Chen R, Sun X, Ni X, Wu Y, Cai L et al. · 2026
- 299Abdalla OS, Mudassir H, Green H, Katarki P · 2025
- 300de Guingand DL, Palmer KR, Bilardi JE, Ellery SJ · 2020
- 301
- 302Ostojic SM, Kavecan I · 2026
- 303
- 304
- 305Stout JR, Pabian PS · 2026
- 306Farfán-Díaz Á, Fuentes Hinojosa C, Andrade Oyarzun M, Garcia-Carrillo E, Molina-Márquez I, Yáñez-Sepúlveda R et al. · 2026
- 307
- 308Nederveen JP, Nilsson MI, Tarnopolsky MA · 2025
- 309Candow DG, Kirk B, Chilibeck PD, Duque G · 2025
- 310Candow DG, Ostojic SM, Chilibeck PD, Longobardi I, Gualano B, Tarnopolsky MA et al. · 2025
- 311Mănescu AM, Hangu SȘ, Mănescu DC · 2025
- 312Smith-Ryan AE, DelBiondo GM, Brown AF, Kleiner SM, Tran NT, Ellery SJ · 2025
- 313Młynarska E, Leszto K, Katańska K, Prusak A, Wieczorek A, Jakubowska P et al. · 2025
- 314Ostojic SM, Candow DG, Tarnopolsky MA · 2025
- 315Stout JR, Kreider RB, Candow DG, Forbes SC, Rawson ES, Antonio B et al. · 2025
- 316Longobardi I, Solis MY, Roschel H, Gualano B · 2025
- 317Han ES, Yancey JR, Yurgelun-Todd DA, Kondo DG, Boxer DJ, Renshaw PF · 2025
- 318Sanchis-Gomar F, Neeland IJ, Ruiz-Lozano P, Alnahar O, Rodriguez F · 2025
- 319Damanti S, Senini E, De Lorenzo R, Merolla A, Santoro S, Festorazzi C et al. · 2024
- 320Conti F, McCue JJ, DiTuro P, Galpin AJ, Wood TR · 2024
- 321Gutiérrez-Hellín J, Del Coso J, Franco-Andrés A, Gamonales JM, Espada MC, González-García J et al. · 2024
- 322Antonio J, Pereira F, Curtis J, Rojas J, Evans C · 2024
- 323Candow DG, Moriarty T · 2024
- 324Gonzalez DE, Forbes SC, Zapp A, Jagim A, Luedke J, Dickerson BL et al. · 2024
- 325
- 326"Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and FunctionCandow DG, Forbes SC, Ostojic SM, Prokopidis K, Stock MS, Harmon KK et al. · 2023
- 327Forbes SC, Candow DG, Neto JHF, Kennedy MD, Forbes JL, Machado M et al. · 2023
- 328Marcotte-Chénard A, Oliveira B, Little JP, Candow DG · 2023
- 329Meftahi GH, Hatef B, Pirzad Jahromi G · 2023
- 330Roberts MD, Moulding B, Forbes SC, Candow DG · 2023
- 331Candow DG, Chilibeck PD, Forbes SC, Fairman CM, Gualano B, Roschel H · 2022
- 332Cordingley DM, Cornish SM, Candow DG · 2022
- 333Forbes SC, Candow DG, Ferreira LHB, Souza-Junior TP · 2022
- 334Candow DG, Forbes SC, Roberts MD, Roy BD, Antonio J, Smith-Ryan AE et al. · 2022
- 335Wax B, Kerksick CM, Jagim AR, Mayo JJ, Lyons BC, Kreider RB · 2021
- 336Arazi H, Eghbali E, Suzuki K · 2021
- 337Smith-Ryan AE, Cabre HE, Eckerson JM, Candow DG · 2021
- 338Candow DG, Forbes SC, Kirk B, Duque G · 2021
- 339Ribeiro F, Longobardi I, Perim P, Duarte B, Ferreira P, Gualano B et al. · 2021
- 340Bongiovanni T, Genovesi F, Nemmer M, Carling C, Alberti G, Howatson G · 2020
- 341Forbes SC, Candow DG, Smith-Ryan AE, Hirsch KR, Roberts MD, VanDusseldorp TA et al. · 2020
- 342Clarke H, Kim DH, Meza CA, Ormsbee MJ, Hickner RC · 2020
- 343Lawler TP, Cialdella-Kam L · 2020
- 344Balestrino M, Adriano E · 2019
- 345Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB · 2019
- 346
- 347Rawson ES, Miles MP, Larson-Meyer DE · 2018
- 348Butts J, Jacobs B, Silvis M · 2018
- 349Potential Adverse Effects of Creatine Supplement on the Kidney in Athletes and BodybuildersDavani-Davari D, Karimzadeh I, Ezzatzadegan-Jahromi S, Sagheb MM · 2018
- 350Jagim AR, Stecker RA, Harty PS, Erickson JL, Kerksick CM · 2018
- 351Rawson ES, Clarkson PM, Tarnopolsky MA · 2017
- 352Farshidfar F, Pinder MA, Myrie SB · 2017
- 353Santesteban Moriones V, Ibáñez Santos J · 2017
- 354Ellery SJ, Walker DW, Dickinson H · 2016
- 355Freire Royes LF, Cassol G · 2016
- 356Trexler ET, Smith-Ryan AE · 2015
- 357Culbertson JY, Kreider RB, Greenwood M, Cooke M · 2010
- 358Tarnopolsky MA · 2010
- 359
- 360Tarnopolsky MA · 2008
- 361Shao A, Hathcock JN · 2006
- 362Ellis AC, Rosenfeld J · 2004
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.